Dalton Venture
VC Fund
Shanghai, China
Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
- Total investments:
- 142
- Last investment:
- Lead investor:
- 37%
Last updated:
For AI agents: llms.txt
Industries Dalton Venture invests in
Stages Dalton Venture invests in
Countries Dalton Venture invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $450k–$5M
- Series A
- $2.8M–$17M
- Series B
- $2.8M–$50M
Investment Focus
Industry
- Health Care 24 (17%)
- Medical 20 (14%)
- Biotechnology 14 (10%)
- Medical Device 10 (7%)
- Manufacturing 9 (6%)
Stage
- Seed 47 (33%)
- Series A 32 (23%)
- Series B 21 (15%)
- Angel 10 (7%)
- Series C 6 (4%)
Country
- China 46 (32%)
- India 33 (23%)
- Canada 1 (1%)
- Singapore 1 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ning Huang
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Qi Sun
Founding Management Partner
|
Founding Management Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NewPro
|
NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible. | Seed / Aug 04, 2026 | |
|
Active Technology
|
Active Technology is a pioneering deep tech startup specialized in developing invasive brain computer interface (BCI) technology. The company integrates flexible electrodes, dedicated chips, and advanced decoding algorithms to target motor, visual, and emotional neural pathways. | $48.9M / Angel / Aug 03, 2026 | |
Gestala
|
Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge. | $61.9M / Angel / Jul 03, 2026 | |
|
Kongshanci
|
Kongshanci specializes in non-invasive brain-computer interfaces and neuromodulation. | Series A / Jun 12, 2026 | |
|
Baiyao Technology
|
Baiyao Technology is a biopharmaceuticals company offering drug and treatment plan development utilizing AI simulation of life processes. | Seed / Jun 05, 2026 | |
Bangyun Medical
|
Bangyun Medical focuses on the research, development, production and sales of high-end surgical wound closure consumables and instruments | $14.5M / Angel / Mar 31, 2026 | |
|
Kangweijian Bio
|
Kangweijian Bio is a health food manufacturer and distributor dedicated to delivering safe, high-quality products and services across global markets, specializing in food and cosmetic raw materials, health food ingredients, pharmaceutical excipients, and animal nutrition. | Series B / Mar 16, 2026 | |
|
Gestala
|
Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge. | $21.8M / Angel / Mar 12, 2026 | |
MaiKeWei Medical
|
MaiKeWei Medical is a national high-tech company. It has an entire system that includes production, sales, and R&D. | Angel / Mar 03, 2026 | |
|
KRay Gene
|
KRay Gene is an innovative biopharmaceutical company focused on the development of ophthalmic and cell therapy drugs, committed to advancing cutting-edge therapies through scientific research and translational medicine to address unmet medical needs. | Series A / Jan 21, 2026 | |
| See all 142 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Dalton Venture invest in?
Dalton Venture invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 142 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dalton Venture's check size?
Dalton Venture typically joins rounds of $450k–$5M at Seed, $2.8M–$17M at Series A and $2.8M–$50M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dalton Venture participates in.
How do I contact Dalton Venture?
Public channels for Dalton Venture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dalton Venture?
The team at Dalton Venture includes Ning Huang (Founding Partner) and Qi Sun (Founding Management Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
